Statistics

Total Visits

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer31

Select a period of time:

Number of views in the range

Views
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer24

Views

Views
January 20251
February 20252
March 202516
April 20252
May 20252
June 20251
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore17
United States4
Brazil2
Spain1
 

Top cities views

Views
Belo Horizonte1
Concórdia1
Council Bluffs1
Dallas1